Age-associated impairment of antitumor immunity in carcinoma-bearing mice and restoration by oral administration of Lentinula edodes mycelia extract

Cancer Immunology, Immunotherapy

Volumn 65, Issue 8, 2016, Pages 961-972

  Ishikawa, Satoru ^a,b   Matsui, Yasunori ^b   Wachi, Satoshi ^b   Yamaguchi, Hiroshi ^b   Harashima, Nanae ^a   Harada, Mamoru ^a  

^a SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

^b Kobayashi Pharmaceutical Co   (Japan)

Author keywords

Aging; IL 6; Inflammation; MDSC; T cell immunity

Indexed keywords

CD11B ANTIGEN; CD4 ANTIGEN; DOXORUBICIN; INTERLEUKIN 6; LENTINULA EDODES EXTRACT; TUMOR NECROSIS FACTOR;

AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; CANCER IMMUNOTHERAPY; CANCER INFILTRATION; CANCER INHIBITION; CANCER LOCALIZATION; CD4+ T LYMPHOCYTE; CELL COUNT; CELL INFILTRATION; COLON CARCINOMA; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; IN VITRO STUDY; IN VIVO STUDY; LENTINULA EDODES; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REGULATORY T LYMPHOCYTE; SENESCENCE; SPLEEN CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; AGE; ANIMAL; BAGG ALBINO MOUSE; COLON TUMOR; HUMAN; IMMUNOLOGY; METABOLISM; NUDE MOUSE; ORAL DRUG ADMINISTRATION; THERAPEUTIC USE; TUMOR CELL LINE;

ADMINISTRATION, ORAL; AGE FACTORS; ANIMALS; CELL LINE, TUMOR; COLONIC NEOPLASMS; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; SHIITAKE MUSHROOMS;

EID: 84975119976     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-016-1857-y     Document Type: Article

References (43)

1. Lustgarten J (2009) Cancer, aging and immunotherapy: lessons learned from animal models. Cancer Immunol Immunother 58:1979–1989
2. Taub DD, Longo DL (2005) Insights into thymic aging and regeneration. Immunol Rev 205:72–93
3. Song I, Kim Y, Chopra R et al (1993) Age-related effects in T cell activation and proliferation. Exp Gerontol 28:313
4. Engwerda C, Fox B, Handwerger B (1996) Cytokine production by T lymphocytes from young and aged mice. J Immunol 156:3621
5. Bloom E, Umehara H, Bleackley R et al (1990) Age-related decrement in cytotoxic T lymphocyte (CTL) activity is associated with decreased levels of mRNA encoded by two CTL-associated serine esterase genes and the perforin gene in mice. Eur J Immunol 20:2309
6. Thoman M (1997) Effects of the aged microenvironment on CD4+ T cell maturation. Mech Ageing Dev 96:75–88
7. Saurwein-Teissl M, Romani N, Grubeck-Loebenstein B (2000) Dendritic cells in old age- neglected by gerontology? Mech Ageing Dev 121:123
8. + T cells in aged mice. J Immunol 176:6586–6593
9. Sharma S, Dominguez A, Lustgarten J (2006) High accumulation of T regulatory cells prevents the activation of immune responses in aged animals. J Immunol 177:8348–8355
10. Grizzle W, Xu X, Zhang S et al (2007) Age-related increase of tumor susceptibility is associated with myeloid-derived suppressor cell mediated suppression of T cell cytotoxicity in recombinant inbred B × D12 mice. Mech Ageing Dev 128:672–680
11. Tsukamoto H, Senju S, Matsumura K et al (2015) IL-6-mediated environmental conditioning of defective Th1 differentiation dampens antitumour immune responses in old age. Nat Commun 6:6702–6716
12. Spaulding CC, Walford RL, Effros RB (1997) Calorie restriction inhibits the age-related dysregulation of the cytokines TNF-α and IL-6 in C3B10RF1 mice. Mech Ageing Dev 93:87–94
13. + B Cells enhance anti-tumor immunity via Th1 and Th17 induction. Aging Cell 11:128–138
14. Donin N, Sinai J, Staroselsky A et al (1997) Comparison of growth rate of two B16 melanomas differing in metastatic potential in young versus middle-aged mice. Cancer Invest 15:416–421
15. Kanno J, Wakikawa A, Utsuyama M et al (1997) Effect of restraint stress on immune system and experimental B16 melanoma metastasis in aged mice. Mech Ageing Dev 93:107–117
16. Itzhaki O, Kaptzan T, Skutelsky E et al (2004) Age-adjusted antitumoral therapy based on the demonstration of increased apoptosis as a mechanism underlying the reduced malignancy of tumors in the aged. Biochim Biophys Acta 1688:145–159
17. Philip M, Rowley DA, Schreiber H (2004) Inflammation as a tumor promoter in cancer induction. Semin Cancer Biol 14:433–439
18. Cahlin C, Körner A, Axeisson H et al (2000) Experimental cancer cachexia: the role of host-derived cytokines interleukin (IL)-2, IL-12, interferon-gamma, and tumor necrosis factor alpha evaluated in gene knockout, tumor-bearing mice on C57Bl background and eicosanoid-dependent cachexia. Cancer Res 60:5488–5493
19. Liu Q, Tan Q, Zheng Y et al (2014) Blockade of fas signaling in breast cancer cells suppresses tumor growth and metastasis via disruption of fas signaling-initiated cancer-related inflammation. J Biol Chem 289:11522–11535
20. Bunt SK, Yang L, Sinha P et al (2007) Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res 67:10019–10026
21. H1 development through IL-6 production to promote tumor progression. Cancer Immunol Res 1:64–76
22. Tanaka K, Ishikawa S, Matsui Y et al (2011) Oral ingestion of Lentinula edodes mycelia extract inhibits B16 melanoma growth via mitigation of regulatory T cell-mediated immunosuppression. Cancer Sci 102:516–521
23. Tanaka K, Ishikawa S, Matsui Y et al (2012) Combining a peptide vaccine with oral ingestion of Lentinula edodes mycelia extract enhances anti-tumor activity in B16 melanoma-bearing mice. Cancer Immunol Immunother 61:2143–2152
24. Tanaka K, Matsui Y, Ishikawa S et al (2012) Oral ingestion of Lentinula edodes mycelia extract can restore the antitumor T cell response of mice inoculated with colon-26 cells into the subserosal space of the cecum. Oncol Rep 27:325–332
25. Kojima H, Akaki J, Nakajima S et al (2010) Structural analysis of glycogen-like polysaccharides having macrophage-activating activity in extracts of Lentinula edodes mycelia. J Nat Med 64:16–23
26. Huang AY, Gulden PH, Woods AS et al (1996) The immunedominant major histocompatibility complex class I-restricted antigens of a murine colon tumor derives from an endogenous retroviral gene product. Proc Natl Acad Sci USA 93:9730–9735
27. Youn JI, Nagaraj S, Colloazo M et al (2008) Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol 181:5791–5802
28. Sinha P, Parker KH, Horn L et al (2012) Tumor-induced myeloid-derived suppressor cell function is independent of IFN-γ and IL-4Rα. Eur J Immunol 42:2052–2059
29. Ostrand-Rosenberg S, Sinha P (2009) Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 182:4499–4506
30. Beury DW, Parker KH, Nyandio M et al (2014) Cross-talk among myeloid-derived suppressor cells, macrophages, and tumor cells impacts the inflammatory milieu of solid tumors. J Leukoc Biol 96:1109–1118
31. Boehmer ED, Goral J, Faunce DE et al (2004) Age-dependent decrease in Toll-like receptor 4-mediated proinflammatory cytokine production and mitogen-activated protein kinase expression. J Leukoc Biol 75:342–349
32. Chelvarajan RL, Collons SM, Van Willigen JM et al (2005) The unresponsiveness of aged mice to polysaccharide antigens is a result of a defect in macrophage function. J Leukoc Biol 77:503–512
33. Bouchlaka MN, Sckisel GD, Chen M et al (2013) Aging predisposes to acute inflammatory induced pathology after tumor immunotherapy. J Exp Med 210:2223–2237
34. Kohman RA, Crowell B, Kusnecov AW (2010) Differential sensitivity to endotoxin exposure in young and middle-age mice. Brain Behav Immun 24:486–492
35. Mirsoian A, Bouchalaka MN, Sckisel GD et al (2014) Adiposity induces lethal cytokine storm after systemic administration of stimulatory immunotherapy regimens in aged mice. J Exp Med 211:2373–2383
36. Young MR, Kolesiak K, Achille NJ et al (2001) Impact of aging on immune modulation by tumor. Cancer Immunol Immunother 50:315–320
37. Tesniere A, Apetoh L, Ghiringhelli F et al (2008) Immunogenic cancer cell death: a key–lock paradigm. Curr Opin Immunol 20:504–511
38. Tongu M, Harashima N, Yamada T et al (2010) Immunogenic chemotherapy with cyclophophamide and doxorubicin against established murine carcinoma. Cancer Immunol Immunother 59:769–777
39. Zhou Y, Bosch ML, Salgaller ML (2002) Current methods for loading dendritic cells with tumor antigen for the induction of antitumor immunity. J Immunother 25:289–303
40. McIlroy D, Gregoire M (2003) Optimizing dendritic cell-based anticancer immunotherapy: maturation state does have clinical impact. Cancer Immunol Immunother 52:583–591
41. Gorelik L, Bar-Dagan Y, Mokyr MB (1996) Insight into the mechanism(s) through which TNF promotes the generation of T cell-mediated antitumor cytotoxicity by tumor bearer splenic cells. J Immunol 156:4298–4308
42. + cytotoxic T lymphocyte- mediated lysis. J Immunol 150:4303–4314
43. Yoshioka Y, Tamesada M, Nagayama A (2009) The Safety of Excessive Intake of the Food Containing Extract of Cultured Lentinula edodes Mycelia (L.E.M.) in Healthy Adult Volunteers. JCAM 6:9–15 (in Japanese.)